OCT Measurement of TM/SC Stiffness in Living Mice
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
July 01, 2015 - December 30, 2017
Grant ID
G2015100
Goals
The most important factor in preventing blindness in glaucoma patients is early diagnosis and effective treatment of the disease. We have developed a way, without touching the eye, to visualize the mouse outflow pathway, ie, the tissues draining fluid from the eye that control intraocular pressure (IOP), as that pathway may be affected by different pressure readings and various glaucoma drug treatments. This project is vital in three ways: 1) we can make glaucoma eyes in mice that mimic the disease in humans in order to test how the outflow tissue of diseased eyes differs from normal eyes; 2) we can treat the glaucoma eyes with newly developed drugs to see whether they are safe and effective for glaucoma; 3) we can apply the information collected from these animals to clinical purposes for glaucoma early diagnosis and effective treatment.
Summary
Lowering intraocular pressure (IOP) is neuroprotective, delaying/preventing vision loss in primary open-angle glaucoma patients. Much of the functional morphologic knowledge about the conventional outflow pathway has been limited to fixed samples, often from patients on long-term medical treatment, and thus is subject to artifact and represents only a “snapshot” in time. In actuality, IOP is dynamic and integrated, and IOP oscillations are dampened by the pressure-dependent conventional outflow tract. The aim of this study is to understand the vibrant response of conventional outflow tissues to changes in IOP and to a conventional outflow drug, in real-time. Specifically, we aim to develop non-invasive methodologies to determine the stiffness of the trabecular meshwork (TM)/Schlemm’s canal (SC) inner wall in young, aged, and corticosteroid-induced glaucoma mouse eyes (plus/minus treatment with a rho kinase inhibitor) using spectral domain OCT. Our study has potential impact for three important clinical unmet needs: (i) early glaucoma diagnosis, (ii) monitoring treatment response and (iii) following disease progression.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute